What's stalling this PBS listing?

Clinect has shone a light on why its epilepsy drug Zyamis has stalled in the post-PBAC process in a new submission to the reimbursement committee.

The Melbourne-headquartered company supplies a range of products in Australia and New Zealand via strategic partnering and product acquisition however it has struggled to secure government subsidy for Zyamis under the right terms.

Zyamis is an oromucosal solution of midazolam, which has traditionally been used as a sedative anaesthetic agent when administered intravenously.